ChinaBio® Today Blog | Talkmarkets | Page 1
News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

All Contributions

Latest Posts
1 to 16 of 234 Posts
1 2 3 ... 15
Week In Review: Biotheus Acquires China Rights To Three Bi-specifics In $142 Million Deal
Biotheus, a Guangdong biopharma, signed a $142 million deal for China rights to three bi-specifics based on a TNFR antibody from Alligator Bio of Stockholm.
Week In Review: Chipscreen Gains 367% Following $148 Million Shanghai STAR IPO
China's Chipscreen Bio traded 367% higher following its $148 million IPO on the Shanghai STAR exchange, raising its market cap to $4.2 billion.
Week In Review: Nanjing King-Friend Invests $95 Million In US Partner, Meitheal Pharma
Nanjing King-Friend Bio invested $95 million in Meitheal Pharma of Chicago, a generic injectables company, raising its holdings to a majority stake.
Week In Review: United Healthcare, A China Hospital Chain, Acquired For $1.4 Billion
This week in deals and financing, United Family Healthcare, a China hospital chain, will be acquired by New Frontier Corp from TPG and Fosun Pharma at an expected value of $1.44 billion.
Week In Review: Wild Trading On Opening Day At Shanghai STAR Exchange; Shenzhen Chipscreen To IPO On STAR Next Week
The first 25 young China high-tech companies to IPO on Shanghai's STAR Exchange soared an average of 140% when they began trading; Shenzhen ChipScreen is expected to IPO on STAR next week.
Week In Review: Three China Biopharmas Announce Plans For Shanghai/Hong Kong IPOs
HitGen of Chengdu, a small molecule discovery CRO, was approved for a $97 million IPO on Shanghai's new STAR Exchange and Shenzhen Chipscreen Biosciences, a profitable company, will IPO on Shanghai's STAR Board.
Week In Review: SinoMab To IPO On Hong Kong Exchange
Hong Kong's SinoMab published its prospectus for a Hong Kong IPO to support its antibody program for autoimmune and oncology mAbs.
Week In Review: Jibeier Pharma Files To Raise $100 Million In IPO On New Shanghai STAR Board
Jibeier Pharma, expects to raise $100 million in the offering. The company, plans to use the funds to build a new drug manufacturing facility and R&D center, and to support its R&D of new drugs along with clinical trials.
Week In Review: Tasly Bio Files For $1 Billion Hong Kong IPO
Shanghai Tasly Biopharma, the biologics arm of Tasly Pharma, has filed a prospectus for a Hong Kong IPO expected to raise up to $1 billion.
Week In Review: Immunotherapies Dominate The Week's China Biopharma News
Beijing's BeiGene will receive a $150 million termination fee as Celgene ends its $1.4 billion co-development partnership for BeiGene's PD-1 candidate.
Week In Review: China Biopharma Announces Nearly $3 Billion In Deals
Vivo Capital, a US-China healthcare investor, raised $1.3 billion for its ninth fund, bringing its assets under management to more than $4.3 billion. Hansoh Pharma staged a $1 billion Hong Kong IPO and then rising 37% in its first trading session.
Week In Review: Frontage, A US-China CRO, Stages $205 Million Hong Kong IPO
Frontage Holdings, a US-China CRO, raised $205 million in a Hong Kong IPO at an $820 million valuation and moved 4.5% higher in its first trading session.
Week In Review: Hansoh's Hong Kong IPO To Raise Up To $1 Billion At $10 Billion Valuation
Jiangsu Hansoh Pharma, a generic/novel drug company, will aim to raise up to $1 billion at a $10 billion valuation in its Hong Kong IPO.
Week In Review: WuXi Biologics Signs LOI For $3 Billion Vaccine Contract
WuXi Biologics signed a partnership LOI with an unnamed vaccine company to supply $3 billion of vaccines over 20 years and build a dedicated manufacturing facility
Week In Review: MGI Tech Raises $200 Million To Manufacture Genomic Sequencing Machines
MGI Tech a Shenzhen maker of gene sequencing machines and a subsidiary of genomics company BGI, completed an A funding of more than $200 million.
Week In Review: Gene Editing Scandal; Can China Biopharma Continue To Expand? News On Three China Life Science IPOs
Regulatory changes are speeding drug development timelines for novel imported drugs in China, and VCs raised over $40 billion in new funding last year. Was 2018 as good as it gets, or can the growth in investment activity continue?
1 to 16 of 234 Posts
1 2 3 ... 15